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Abstract
Background: Glioblastoma (GBM) is a complex disease with extensive molecular and
transcriptional heterogeneity. GBM can be subcategorized into four distinct subtypes;
tumors that shift towards the mesenchymal phenotype upon recurrence are
generally associated with treatment resistance, unfavorable prognosis, and the
infiltration of pro-tumorigenic macrophages.
Results: We explore the transcriptional regulatory networks of mesenchymalassociated tumor-associated macrophages (MA-TAMs), which drive the malignant
phenotypic state of GBM, and identify macrophage receptor with collagenous
structure (MARCO) as the most highly differentially expressed gene. MARCOhigh TAMs
induce a phenotypic shift towards mesenchymal cellular state of glioma stem cells,
promoting both invasive and proliferative activities, as well as therapeutic resistance
to irradiation. MARCOhigh TAMs also significantly accelerate tumor engraftment and
growth in vivo. Moreover, both MA-TAM master regulators and their target genes are
significantly correlated with poor clinical outcomes and are often associated with
genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/
mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes. We
further demonstrate the origination of MA-TAMs from peripheral blood, as well as
their potential association with tumor-induced polarization states and
immunosuppressive environments.
Conclusions: Collectively, our study characterizes the global transcriptional profile of
TAMs driving mesenchymal GBM pathogenesis, providing potential therapeutic
targets for improving the effectiveness of GBM immunotherapy.
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Introduction
Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults [1].
The current standard treatment regimen primarily provides palliative treatment and
leads to a median survival of less than 15 months despite aggressive therapeutic interventions, including maximum surgical resection followed by chemo- and radiotherapy
[2]. GBMs can be subcategorized into distinct subtypes based on their transcriptional
cellular state and accompanying unique genomic alterations [3, 4]. This expressionbased classification system has emerged as an important concept in understanding the
biological behavior and genomic complexity of GBM. Its significance has been increasingly recognized owing to the distinct clinical response of each subtype to current
treatment strategies, their diverse cellular origins and differentiation hierarchies, and
the infiltration and accumulation of tumor-associated immune cells within the surrounding environment [4–8].
Tumor-associated macrophages (TAMs) within the GBM niche include a mixture of
heterogeneous subpopulations that are derived from two major sources: brain-resident
microglial cells and peripheral blood-derived monocytes [9–11]. These macrophages
present specific cell-surface antigens and play distinct functional roles based on their
cellular origin and tumor-induced polarization state [12, 13]. M1-polarized macrophages have been recognized for their potent anti-tumor immune cytotoxicity function, while M2 macrophages promote tumor progression through modulation of
immune-suppressive environment and pro-tumorigenic functions [14]. Notably,
GBMs demonstrate a high degree of subtype plasticity, manifesting dynamic subtype transitions between diagnosis and recurrence [4, 6, 15]. In particular, mesenchymal transformation has been generally associated with limited clinical response
to current standard therapies, largely due to the infiltration of pro-tumorigenic immune cells such as TAMs [16–18].
GBM contains a subpopulation of highly tumorigenic stem-like cells known as glioma
stem cells (GSCs); these cells possess an innate perpetual self-renewal and differentiation ability [19, 20]. While previous studies have identified molecular links between
GSCs and tumor microenvironment (TME) that promote recruitment of TAMs within
the perivascular region [21–25], the major transcriptional regulatory networks of TAMs
driving the malignant phenotypic state of mesenchymal GBM still remain obscure. To
address such challenges, we performed comprehensive transcriptome analyses of
mesenchymal-associated tumor-associated macrophages (MA-TAMs) and identified its
unique signature and core master regulators that govern their transcriptional cellular
state. Furthermore, MA-TAMs promoted mesenchymal trans-differentiation of GSCs
in vitro and in vivo
and confer unfavorable prognosis in GBM patients. Collectively, our results unraveled
the dynamic transcriptomic networks of MA-TAMs that govern mesenchymal transition of GSCs and present potential immunotherapeutic targets that can be exploited in
the field of GBM treatment.
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Results
Identification of MA-TAM-encoding genes and its transcriptional master regulators

To identify MA-TAM-specific gene signature and its transcriptional master regulators
that potentially govern mesenchymal cellular differentiation of GSCs, TAM-enriched
subpopulations were identified and isolated from human primary GBM specimens via
fluorescence-activated cell sorting (FACS) and subjected to whole-transcriptome sequencing (WTS). Isolated TAMs were classified as either MA-TAMs or non-MATAMs based on subtype classification of the corresponding tumor cells [4]. We first
identified MA-TAM-encoding genes by extracting a set of transcriptomes from isolated
MA-TAMs that were highly correlated with mesenchymal activity of the corresponding
tumor cells (Additional file 1: Figure S1). Thereafter, we selected candidate genes that
were uniquely expressed by non-malignant cells using GBM orthotopic patient-derived
xenografts (PDX) models [26], which we considered as bona fide tumor-associated stromal/immune cells. The resulting genes consisted of various key macrophage-associated

Fig. 1 Identification of transcriptional regulatory networks of mesenchymal-associated tumor-associated
macrophages (MA-TAMs). a Heatmap representation of MA-TAM encoding genes in TAMs that were
isolated from three mesenchymal (MA-TAMs) and six non-mesenchymal (non-MA-TAMs) tumor specimens.
b Gene Set Enrichment Analysis (GSEA) of PPARG, BATF, and SPI1 in MA-TAM compared to non-MA-TAM
(upper panel). Global regulatory networks between MA-TAM master regulators (blue) and their target genes
(red) (bottom panel). Positive and negative interactions between master regulators and their target genes
are represented in green and red, respectively. Master regulators with P < 0.05 are highlighted in boldfaced
blue. c Scatter plot correlation between MA-TAM signature score and master regulator activity in 91
longitudinal pair samples. Recurrent tumors were categorized into two groups: mesenchymal and nonmesenchymal. d Multiplex immunohistochemical analysis of glioblastoma specimens classified as either
mesenchymal or non-mesenchymal. The co-localization of CD68, MARCO, BATF, PPARG, SPI1, and YKL40 are
indicated with white arrows
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molecules, including macrophage receptor with collagenous structure (MARCO), chemokine (C-C motif) ligand 7 (CCL7), and matrix metallopeptidase 8 (MMP8) and were
significantly enriched for inflammatory response and activation of various immuneassociated pathways (Fig. 1a, Additional file 1: Figure S2). Using the previously established regularized gradient boosting machine (RGBM) algorithm [27–29], we reconstructed glioma-specific global regulatory networks from 1250 mRNA profiles obtained
from The Cancer Genome Atlas (TCGA) and applied them to our MA-TAM gene signature. As a result, we identified twenty-one candidate transcriptional master regulators, including peroxisome proliferator-activated receptor gamma (PPARG), Spi-1
proto-oncogene (SPI1), and basic leucine zipper ATF-like transcription factor (BATF)
(Fig. 1b, Additional file 1: Figure S3).
Because recent large-scale longitudinal GBM studies have demonstrated a high degree of subtype plasticity during tumor evolutionary dynamics [4, 6, 30], we evaluated
transcriptome shifts in MA-TAM encoding genes and their core regulators between
diagnosis and relapse in ninety-one paired gliomas. Notably, we discovered significant
correlations between increased levels of MA-TAM target genes and their master regulators with subtype transitions into the mesenchymal cellular state. (Fig. 1c). Additionally, multi-color immunohistochemistry (IHC) analyses of human GBM specimens
demonstrated prevalence of putative MA-TAM master regulators and their target
genes, including MARCO, in mesenchymal-classified tumors, further confirming the
authenticity and feasibility of our systematic process to identify MA-TAM transcriptional networks (Fig. 1d and Additional file 1: Figure S4). Collectively, our results have
identified potential key molecules of TAMs that promote the malignant state of mesenchymal GBM.
MARCOhigh TAMs drive mesenchymal phenotypic state of GSCs in vitro

To assess whether MA-TAM master regulators govern the transcriptome expression
levels of their target genes, we generated an overexpression construct of Pparg and
transduced it into freshly harvested mouse peritoneal macrophages. Notably, overexpression of Pparg significantly increased the expression levels of MA-TAM-encoding
genes, including Marco, Ccl7, formyl peptide receptor 3 (Fpr3), and Amphiregulin
(Areg) (Fig. 2a, b). Conversely, disruption of Pparg, Batf, or Spi1 expression via shRNAmediated knockdown considerably attenuated their target gene expression levels
in vitro (Fig. 2c), highlighting a crucial role of the master regulators for the maintenance of MA-TAM-encoding gene expressions. As previous studies have explored the
potential association between the density of GSCs with recruitment of TAMs [31, 32],
we investigated whether MA-TAM-associated molecules could potentially drive mesenchymal transformation and the malignant cellular state of GSCs. As expected, treatment with either recombinant MARCO or CCL7 proteins significantly increased the
expression levels of both mesenchymal- and stemness-associated markers, including
CD44, homeobox protein NANOG (NANOG), leukemia inhibitory factor (LIF), and
matrix metallopeptidase 2 (MMP-2) [33, 34] (Fig. 2d and Additional file 1: Figure S5A).
Furthermore, both MARCO and CCL7 promoted the upregulation of transcription coactivator with PDZ-binding motif (TAZ), which has been suggested as a key transcriptional coactivator regulating mesenchymal trans-differentiation in malignant gliomas
[7] (Fig. 2e and Additional file 1: Figure S5B).
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Fig. 2 MARCO promotes mesenchymal, invasive, and migratory phenotypes, as well as therapeutic resistance
to irradiation. a qRT-PCR analysis to determine the effects of Pparg on the mRNA expression levels of the MATAM genes Marco, Ccl7, Fpr3, and Areg in mouse peritoneal macrophages. b Representative
immunofluorescence images of Pparg and Marco in mouse peritoneal macrophages transduced with either
control or Pparg. c qRT-PCR analysis to determine the effects of siPPARG, siBatf, or siSpi1 on the mRNA
expression levels of the MA-TAM genes Marco, Ccl7, Cd180, Cr2, Mmp8, and Areg in mouse peritoneal
macrophages. d qRT-PCR analysis to determine the effects of MARCO or CCL7 on the expression of
mesenchymal, stemness, and cellular invasion markers including CD44, NANOG, LIF, and MMP-2 in two GSC
samples. e Immunoblot analysis of CD44, TAZ, and NANOG activity in GSCs treated with either control, MARCO,
or CCL7; α-tubulin was used as a loading control. f Representative images of 3D invasion assays in GSCs treated
with either control, monocyte-derived CM, MARCOlow TAM-derived CM, or MARCOhigh TAM-derived CM (upper
panel). Immunofluorescence images of CD44 intracellular domain and DAPI (red and blue, respectively; lower
panel). g Representative images of tube formation assay (left panel) and representative bar graphs (right panel)
for HUVECs. h The 1/stem cell frequency of GSCs treated with either monocyte-derived CM, MARCOlow TAMderived CM, or MARCOhigh TAM-derived CM and subjected to 2 Gy ionizing radiation. Stem cell frequency was
calculated by extreme limiting dilution analysis. i qRT-PCR analysis to determine the effects of monocytederived CM, MARCOlow TAM-derived CM, and MARCOhigh TAM-derived CM on mesenchymal, stemness, and
cellular invasion markers in GSCs. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data shown in a, c, d, and i are
representative of three independent and reproducible experiments. Data shown in b and e–h are
representative of two independent and reproducible experiments

Various cytokines released from TAMs modulate the cellular state and functional
roles of adjacent GSCs and differentiated tumor cells in GBMs [13]. To interrogate the
cellular effects of TAM-derived MARCO in vitro, we isolated TAMs from GBM PDX
models based on the expression of MARCO and control monocytes from healthy mice.
Afterwards, we generated conditioned media (CM) from monocyte, MARCOlow, or
MARCOhigh TAMs and studied their effects on tumor cellular phenotypes. CM from
MARCOhigh TAMs significantly upregulated both invasive and angiogenic activities of
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GSCs and human umbilical vein endothelial cells (HUVECs), respectively (Fig. 2f, g)
coupled with therapeutic resistance to irradiation (Fig. 2h, Additional file 1: Figure S6),
which are representative characteristics of mesenchymal GBMs. Consistently, we discovered that MARCOhigh TAM-derived CMs significantly elevated the transcriptional
expression levels of mesenchymal-, stemness-, and invasion-associated molecules
(Fig. 2l). Conversely, treatment of anti-MARCO antibodies significantly reduced the expression level of MARCO and prevented mesenchymal trans-differentiation of GSCs.
(Additional file 1: Figure S7). Collectively, our results demonstrate that MARCOhigh
TAMs drive mesenchymal transformation and the aggressive phenotypes of GBM.

MARCOhigh TAMs accelerate tumor growth and promote mesenchymal phenotypes
in vivo

TAMs and tumor cells generate a reciprocal feedback loop that leads to an
immuno-suppressive and pro-tumorigenic environment. To evaluate whether MATAMs promote aggressive tumor growth in vivo, we generated orthotopic GBM
PDX mouse models via co-injection of non-mesenchymal GSCs with either normal
mouse monocytes, MARCOlow TAMs, or MARCOhigh TAMs. Following intracranial
implantation, we observed accelerated tumor engraftments followed by shortened
survival span in PDX models that were co-injected with MARCOhigh TAMs

Fig. 3 Effects of MARCOhigh TAMs in vivo and ex vivo. a Representative hematoxylin and eosin staining of
mouse brains orthotopically co-implanted with GSCs and either control, monocytes, MARCOlow TAMs, or
MARCOhigh TAMs. Each group was injected with 5 mice. b Kaplan-Meier survival curve analysis of
the mouse models. c Representative immunohistochemical images of mesenchymal markers including
CD44, YKL40, TOP2A, SERPINE1, and BCL2A1 in mouse models. d qRT-PCR analysis of stemness and invasive
markers from ex vivo tumor specimens isolated from mouse models. e The 1/stem cell frequency of GSCs
isolated from model mice and subjected to 2 or 5 Gy ionizing radiation. *P ≤ 0.05, **P ≤ 0.01, ***, P ≤ 0.001.
Data shown in c and e are representative of two independent and reproducible experiments. Data shown
in d are representative of three independent and reproducible experiments
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compared to either monocyte- or MARCOlow-TAM-derived mouse models (Fig. 3a,
b, Additional file 1: Figure S8A). Furthermore, immunohistochemical analyses demonstrated enrichments of key mesenchymal molecules including CD44, chitinase-3like protein 1 (YKL-40), and topoisomerase II alpha (TOP2A) in non-mesenchymal
GSCs that were co-injected with MARCOhigh TAMs (Fig. 3c, Additional file 1: Figure S8B), which simultaneously promoted both invasive and stem-like properties of
GSCs (Fig. 3d). Notably, ex vivo tumors originating from MARCOhigh-TAM PDX
models demonstrated acquired resistance to irradiation, as shown by their enhanced sphere-forming capacity, suggesting that active crosstalk between GSCs and
MARCOhigh TAMs provides an innate ability for tumor cells to circumvent therapeutic vulnerability (Fig. 3e).

Genomic correlates and cellular origins of MA-TAMs

To evaluate whether MA-TAM encoding genes and their master regulators reflect
overall clinical prognosis in GBM, we stratified primary GBM patients based on
their MA-TAM signature scores from TCGA dataset [35]. Survival analysis revealed
that the MA-TAM signature and its master regulator activity were significantly
correlated with reduced clinical outcomes (Fig. 4a, Additional file 1: Figure S9).
We then sought to identify genomic correlates, including mutations (single

Fig. 4 Genomic correlates of MA-TAM and its association with cellular origination and polarization state. a
Kaplan-Meier survival curve analysis of 373 GBM patients based on MA-TAM signature score. b Genomic
landscape of 133 MA-TAMhigh and MA-TAMlow tumors (left panel). Somatic mutations, including singlenucleotide variations (SNVs), and small insertions/deletions, and copy number alterations, are shown. All
somatic mutations with an allele frequency of > 5% are shown. Percentage of altered cases in key GBM
driver pathways (right panel). c tSNE analysis of 3589 single-cell transcriptomes. Cell clusters are differentially
colored and annotated based on each distinct cellular compartment (left panel). Expression of cell-typespecific signatures, polarization state, microenvironmental state overlaid on the tSNE space (right panel). d
MA-TAM signature scores (upper panel) and master regulator activity (lower panel) in IVY Glioblastoma Atlas
Project (IGAP) dataset. Cellular Tumor (CN; n = 111), hyperplastic blood vessels (HBV; n = 22), microvascular
proliferation (MVP, n = 28), pseudo-palisading cells around necrosis (PCAN, n = 40), peri-necrotic zone (PNZ,
n = 26), infiltrating tumor (IT, n = 24), and leading edge (LE, n = 19). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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nucleotide variations and small insertions/deletions) and copy number alterations,
that were significantly enriched in tumors with high MA-TAM infiltration. Consistent with previous reports, MA-TAMhigh tumors exhibited enrichments of NF1 genomic aberrations, which has been speculated to drive recruitment of TAMs and
microglial cells [4]. Although statistically not significant, we also discovered that
MA-TAMhigh tumors showed more frequent dysregulation in the phosphoinositide
3-kinase (PI3K) pathway, marked by genomic alterations in the phosphatase and
tensin homolog (PTEN), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha (PIK3CA), and phosphoinositide-3-kinase regulatory subunit 1
(PIK3R1) genes (45% vs. 32%; Fig. 4b). Previous studies have postulated that dysregulation of the PI3K pathway, specifically via PTEN loss, generates an immunosuppressive environment [36, 37]; thus, we suspect that infiltration by MA-TAMs
could potentially contribute to such malignant state as well. Conversely, MATAMlow tumors primarily demonstrated activation of various receptor tyrosine kinase (RTK)-encoding molecules, including epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor alpha (PDGFRA), and MET proto-oncogene
(MET) (75% vs. 60%; Fig. 4b).
To dissect and delineate the transcriptional profiles of MA-TAMs at a single-cell
resolution, we curated gene expression profiles of 3589 single cells, comprising both
neoplastic and non-neoplastic cells, using publicly available datasets [38]. Using the
previously established t-distributed stochastic neighbor embedding (tSNE) parameters,
we confirmed twelve distinct cell type clusters and evaluated the transcriptional expression levels of MA-TAM signatures in the myeloid cell compartments (Fig. 4c). Notably,
myeloid cells were segregated into two distinct clusters based on the expression of
MA-TAM-associated genes. Of the two primary myeloid clusters, we discovered significant co-enrichment of the MA-TAM signature with MARCO and blood-derived monocytes, suggesting that MA-TAMs mainly originated from peripheral blood. MA-TAMpositive cells also demonstrated enrichment of M2 macrophage signature and immunosuppressive environment, further consolidating their pro-tumorigenic potential (Fig. 4c).
Using another publicly available single-cell dataset, we have determined whether the
expression level of the MA-TAM signature was inherent in mesenchymal tumors [39].
As suspected, PJ017 and PJ032 tumors demonstrated predominance of mesenchymal
tumor cells with enrichments of MA-TAM signature activity (Additional file 1: Figure
S10). Furthermore, we have performed scTHI (single cell Tumor-Host Interaction) to
identify significantly activated ligand-receptor interactions between mesenchymal
tumor cells and MARCO+ TAMs. Notably, we have detected a total of 598 interactive
pairs, among which 20 of them were involved in secreted factor encoding molecules,
including CCR1-CCL5, CCR5-CCL5, SPP1-CD44, CSF1R-CSF3, and SPP1-ITGA5.
(Additional file 1: Figure S11). Our results were further consolidated by cytokine arraybased characterization where conditioned media that are derived from MARCOhigh
TAMs demonstrated high expression levels of SPP1, CCL5, CCL12, CXCL10, CXCL16,
G-CSF, and MPO (Additional file 1: Figure S12).
The anatomical structure of GBM includes unique cellular compartments in the
tumor microenvironment, and the intra-tumor heterogeneity is accompanied by
distinct gene expression patterns [40–42]. To further interrogate the cellular origin
of MA-TAMs, we quantified the expression levels of the MA-TAM signature using
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the Ivy Glioblastoma Atlas Project (IGAP) dataset [42]. Interestingly, the expression
of both MA-TAM encoding genes and their transcriptional master regulators were
highly enriched in cell populations that were derived from peri-necrotic and vascular zones, which are known to be the primary locations of blood-derived monocytes (Fig. 4d, Additional file 1: Figure S13).

Discussion
Current immunotherapeutic strategies primarily focus on exploitation of immunecheckpoint molecules in cytotoxic T cells to combat tumor progression [43]. While a
subset of immune cells is customarily tumoricidal, others adopt a protumoral phenotype that is attributable to tumor malignant transformation. Given the recognition of
diverse immune cell population in TME, identifying a key immunomodulatory in each
disease entity has become the utmost importance. GBM is a unique disease that is often
devoid of lymphoid cells, and TAMs constitute a major source of innate immune cells
in the GBM environment and control key cellular dynamics leading to the evasion of
immune surveillance functions [41, 44–46]. Recent studies have highlighted dynamic
interactions between pro-tumorigenic TAMs and GSCs that lead to global immunosuppressive environment driving GBM pathogenesis [41, 45]. For example, GSCs preferentially secrete various cytokines to recruit monocyte-derived TAMs, which subsequently promote GSC maintenance, therapeutic resistance, and tumor recurrence [22,
24, 41, 47]. Extensive research has outlined the prevalence of TAM infiltration, specifically in mesenchymal GBMs [4, 46, 48]; thus, the molecular characterization of MATAM populations could provide new therapeutic windows for improving tumor-specific immunity. In the present study, we identified global transcriptional regulatory
networks in MA-TAMs that drive mesenchymal transformation and malignancy in
GSCs. Using reverse-engineering algorithms, we discovered a set of master regulators that modulate the transcriptional activity in MA-TAM encoding molecules.
We also demonstrated that the upregulation of MA-TAM-associated gene signatures was significantly correlated with mesenchymal trans-differentiation during
GBM evolutionary dynamics and identified MARCO as one of the most robustly
expressed genes in MA-TAMs.
MARCO is a class A scavenger receptor that has been involved in essential macrophage programs, including phagocytosis and inflammation. Recent reports have recognized MARCO as a potential therapeutic target that is often overexpressed and
involved in tumor microenvironment composition and promote poor prognosis across
multiple cancer types. Furthermore, the expression level of MARCO could be upregulated through activation of TGF-β and IL-10, which subsequently generates immunosuppressive environment. We discovered that treatment with MARCOhigh TAMderived CM transformed non-mesenchymal GSCs into a more aggressive cellular state,
manifesting key mesenchymal characteristics including increased cellular invasion, migration, and therapeutic resistance to ionizing radiation. The co-implantation of MARCOhigh TAMs with non-mesenchymal GSCs led to transcriptome profiles similar to
those of mesenchymal tumor cells, modulating the essential invasive and stem cell-like
properties of GSCs. Furthermore, MARCOhigh TAMs demonstrated significantly accelerated tumor growth and reduced survival rate in patient-derived xenograft models. Ex
vivo tumor cells also developed global resistance to irradiation, as shown by their
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enhanced clonogenic growth. Moreover, we discovered that both MA-TAM transcriptional regulators and their target genes were associated with significantly worse prognosis in GBM patients. Furthermore, MA-TAMhigh tumors were marked by frequent
genomic ablations of NF1 and PI3K pathway components, indicating the essential role
of pathogenic activation of downstream effectors mediated by loss of NF1 and PI3K/
AKT/mTOR signaling in GBM tumor cells for the induction and maintenance of MATAMs in GMB tumor microenvironment [4, 46, 48–50]. Single-cell analysis suggested
the potential cellular origin of MA-TAMs as blood-derived monocytes, as well as coenrichments of MA-TAMs with M2 macrophages and immunosuppressive environment. Notably, MARCO, a key protein within a subset of macrophages that are involved in phagocytosis, inflammation, and others [51], has been implicated as a new
immune target for anti-TAM treatment for treating various solid tumors, including
non-small-cell lung carcinoma, melanoma, and breast cancer [52].
In conclusion, our findings provide novel insights into the dynamic regulatory networks of MA-TAMs and their profound effects in GBM pathogenesis. As the infiltration of pro-tumorigenic TAMs is a key hallmark of tumor propagation, progression,
and response to therapy, in-depth molecular studies of MA-TAM encoding molecules
and their master regulators warrant further investigation to facilitate future immunotherapeutic approaches to treat GBM.

Materials and methods
Glioblastoma patient-derived specimens and primary cell culture

GBM tumor specimens and corresponding clinical records were obtained from patients
undergoing surgery at the Samsung Medical Center (Seoul, Korea) in accordance with
the guidelines of the institutional review board. Informed consent was obtained from
each patient prior to the study. This work was performed in compliance with all relevant ethical regulations for research using human specimens. Surgical samples were either snap-frozen using liquid nitrogen for genomic analysis or enzymatically
dissociated into single cells using Liberase TM (Roche Diagnostics, Basel, Switzerland)
and cultured in neurobasal medium (Gibco, Waltham, MA, USA).

Isolation of tumor-associated macrophages

As reported previously [11, 23–25], fresh tumor tissue specimens were subjected to
FACS to isolate CD45+/CD11b+ TAMs. CellQuest Acquisition (BD Pharmingen, San
Jose, CA, USA) and FlowJo software (Tree Star, Ashland, OR, USA) were used to acquire and quantify the intensity and distribution of fluorescence signals.

Whole-transcriptome sequencing

RNA-seq libraries were prepared using the Illumina TruSeq RNA Sample Prep kit. Sequenced reads were mapped onto the reference human genome (hg19) using GSNAP.
The initial BAM alignment files were sorted and summarized into BED files using
SAMtools and bedTools. The BED files were used to calculate the reads per kilobase of
transcript per million reads (RPKM) values for each gene using the DEGseq package.
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MA-TAM gene expression signature

Gene expression profiles of nine human TAM samples were subjected to gene signature extraction. Genes with maximum log2(RPKM+ 1) values < 1 were removed, and
the resulting 12,497 genes were evaluated to identify positive correlations with GBMintrinsic mesenchymal activity in the corresponding tumor cells. A total of 614 genes
(P < 0.05 and r > 0.7) were further subjected to identify bona fide tumor-associated stromal/immune genes based on transcriptome analysis of orthotopic GBM PDX models.
A total of 105 genes were selected to represent the MA-TAM-specific gene signature.

MA-TAM master regulator analysis

To identify master regulators of the MA-TAM gene signature, gene expression profiles
were curated from MA-TAMs and non-MA-TAMs and assembled into a transcriptional network using the RGBM algorithm developed in our previous works [28, 29,
53]. RGBM algorithm integrates the active binding network and gene expression profiles using a machine learning framework based on gradient boosting machines as detailed in [29]. Gene Set Enrichment Analysis (GSEA) was used to identify network hubs
whose regulon was significantly enriched with the MA-TAM siganture. First, an active
binding network was constructed and used as an a priori mechanistic network of connections between transcription factors (TFs) and their target genes. The active binding
network was reconstructed for 2532 unique motif position weight matrices corresponding to 1203 unique TFs to identify 6,897,782 binding sites in the promoter regions of
12,985 targets (± 5 kb from the transcription start site) using the “Find Individual Motif
Occurrences” tool (P < 1 × 10−5, average width 13.5 bp, hg19 assembly). These binding
sites were overlapped with the open/active chromatin state (TssA, TssFlnkm, TssFlnkU,
TssFlnkD, Tx, EnhG1, EnhG2, EnhA1m, and EnhA1) as determined using
ChromHMM v.1.10 across 98 epigenomes from the Roadmap Epigenomics project (18state model). The number of non-overlapping sites that overlapped with at least 1 bp of
the previously identified 6,897,782 motif sites was 399,187 (hg19; average width 2840
bp), which corresponded to 1,874,570 unique TF-target (Motif + Enhancer) connections between 434 TFs and 12,985 targets. The reduced number of TFs was due to gene
symbol consolidation among different data sources. The active binding network consisted of 6,652,518 overlapping active sites corresponding to 1,959,125 unique TF associations between 1779 TFs and 51,705 targets.

Orthotopic GBM PDX mouse models

All mouse experiments were performed according to the guidelines of the Animal Use
and Care Committees at Samsung Medical Center and the Association for Assessment
and Accreditation of Laboratory Animal Care-accredited guidelines. Female 6–8-weekold BALB/c nude mice were used for intracranial implantation. Patient-derived glioma
stem cells (1 × 105 per mouse) and monocytes or TAMs (1 × 105 per mouse) were coinjected into the brains of mice by stereotactic intracranial injection (coordinates: 2 mm
anterior, 2 mm lateral, 2.5 mm depth from the dura). Mice were sacrificed either when
they showed 25% body weight loss or when neurological symptoms (lethargy, ataxia,
and seizures) were observed.
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Immunohistochemistry

Orthotopic PDXs were fixed with 4% paraformaldehyde in phosphate-buffered saline
(PBS; Gibco) and embedded in paraffin. Sectioned slides were blocked with 10% horse
serum and permeabilized with 0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO,
USA). Samples were probed with primary antibodies against the following proteins:
CD68 and YKL-40 (Abcam, Cambridge, UK), CD163 (Santa Cruz Biotechnology, Dallas, TX, USA), oligodendrocyte TF 2 (R&D Systems, Minneapolis, MN, USA), CD44
(Sigma-Aldrich), B cell lymphoma 2-related protein A1 and Top2A (LSBio, Seattle,
WA, USA), and serpin family E member 1 (Novus Biologicals, Centennial, CO, USA).
Immunoreactivity was quantified using a Tissue FAXS system (Tissuegnostics USA,
Tarzana, CA, USA). Scanned images were analyzed with HistoQuest cytometry software. The threshold signal intensity was determined relative to the negative control.

Real-time reverse-transcriptase PCR

Total RNA was isolated using RNeasy Mini kit and cDNA was synthesized using RT2
First Strand kit (Qiagen). Quantitative reverse-transcriptase PCR (qRT-PCR) was performed on the 7900HT Fast Real-time PCR system (Applied Biosystems, Foster City,
CA, USA) using RT2 SYBR Green qPCR Mastermix (Qiagen, Hilden, Germany). The
following primers were used: Human LIF forward (Fw) 5′-TCTTGGCGGCAGGAGT
TG-3′, reverse (Rev) 5′-CCGCCCCATGTTTCCA-3′; Human NANOG Fw 5′-TTTG
TGGGCCTGAAGAAAACT-3′, Rev. 5′-AGGGCTGTCCTGAATAAGCAG-3′; Human ID1 Fw 5′-CTACGACATGAACGGCTGTTACTC-3′, Rev. 5′-TGGCTCGGCC
AGGACTAC-3′; Human SOX2 Fw 5′-TGCGAGCGCTGCACAT-3′, Rev. 5′TCATGAGCGTCTTGGTTTTCC-3′; Human OLIG2 Fw 5′-ATAGATCGACGCGA
CACCAG-3′, Rev. 5′-ACCCGAAAATCTGGATGCGA-3′; Human SERPINE1 Fw 5′ACCGCAACGTGGTTTTCTCA-3′, Rev. 5′-TTGAATCCCATAGCTGCTTGAAT-3′;
Human CD44 Fw 5′-AGAAGGTGTGGGCAGAAGAA-3′, Rev. 5′-AAATGCACCA
TTTCCTGAGA-3′; Human MMP8 Fw 5′-TCTTCCTCCACACACAGCTTG-3′, Rev.
5′-CTGCAACCATCGTGGCATTC-3′; Human β-actin Fw 5′-AGAAAATCTGGCAC
CACACC-3′, Rev. 5′-AGAGGCGTACAGGGATAGCA-3′; Mouse MARCO Fw 5′GGGTCAAAAAGGCGAATCTTTC-3′, Rev. 5′-CCCTCTGGAGTAACCGAGCA-3′;
Mouse CD180 Fw 5′-TAGGTCTCAATGAAATTCCTGGC-3′, Rev. 5′-AATCTGGC
ACCTGGTTAAATCC-3′; Mouse GPR18 Fw 5′-CACCCTGAGCAATCACAACCA-3′,
Rev. 5′-AGTGACATTAACAAACAGCCCA-3′; Mouse KYNU Fw 5′-GTCAAGCCTG
CGTTAGTGG-3′, Rev. 5′-CTCGCGGCAAGTCTTCAGAG-3′; Mouse TGM2 Fw 5′GACAATGTGGAGGAGGGATCT-3′, Rev. 5′-CTCTAGGCTGAGACGGTACAG-3′;
Mouse SPI1 Fw 5′-ACAGCATCTGGTGGGTGGAC-3′, Rev. 5′-GCCTGTCTTG
CCGTAGTTGC-3′; Mouse PPARG Fw 5′-GCTGAACGTGAAGCCCATCG-3′, Rev.
5′-GGCGAACAGCTGAGAGGACT-3′; Mouse BATF Fw 5′-CAGCTTCAGCCGCT
CTCCTC-3′, Rev. 5′-AGGGTGTCGGCTTTCTGTGT-3′; Mouse CCL7 Fw 5′-GGTG
TCCCTGGGAAGCTGTT-3′, Rev. 5′-GCCTCCTCGACCCACTTCTG-3′; Mouse
CD180 Fw 5′-GGCCTCCAATCGCATCAGCA-3′, Rev. 5′-GGCCTCCAATCGCA
TCAGCA-3′; Mouse MMP8 Fw 5′-GCCTCGATGTGGAGTGCCTG-3′, Rev. 5′GGTGAAGGTCAGGGGCGATG-3′; Mouse CR2 Fw 5′-CTGCTTCGTGCCCTTCCA
CA-3′, Rev. 5′-CGCTGATGACTCGAGCCTGG-3′; Mouse GPR18 Fw 5′-ACCTGG
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AGTCAACCTCCCCC-3′, Rev. 5′-CATCCTGGCACTGGCTCTGG-3′; Mouse KYNU
Fw 5′-AGGAGACTCGATCGCCGTGA-3′, Rev. 5′-ACAAAGGCACCAGCCAGACC3′; Mouse S100A8 Fw 5′-GGAGAAGGCCTTGAGCAACC-3′, Rev. 5′-TGTGAGAT
GCCACACCCACT-3′; Mouse FPR3 Fw 5′-GCTGCCGAATCTGGGGAGTC-3′, Rev.
5′-TGGGAACAGCCTCTGGACGA-3′; Mouse PHACTR2 Fw 5′-TCTCGTCCCA
GAGCACCCAA-3′, Rev. 5′-TTGCTTGTGGCCTGCTCCTC-3′; Mouse AREG Fw 5′GAGAACTCCGCTGCTACCGC-3′, Rev. 5′-GAGAACTCCGCTGCTACCGC-3′;
Mouse β-actin Fw 5′-ATGGTGGGAATGGGTCAGAA-3′, Rev. 5′-CCATGTCGTC
CCAGTTGGTAA-3′.
Generation of CM

A total of 1 × 106 monocytes, MARCOlow TAMs, or MARCOhigh TAMs were cultured
in neurobasal medium for 18 h. The supernatants were harvested, centrifuged, and filtered through a 0.40-μm filter to obtain CM.
3D in vitro invasion assay

A microfluidic device was designed to evaluate the invasive potential of GSCs. GSCs
from each CM-treated group were prepared at a density of 1.5 × 106 cells/ml. After inducing the attachment of cells to the side of the collagen scaffolds by gravity, the device
was placed in a vertical position in a humidified CO2 incubator at 37 °C for 2 h. After
cell attachment, the culture medium was refreshed every 24 h for 3 days.
Evaluation of radiation resistance via neurosphere-forming limiting dilution assay

For ex vivo analysis of GSCs co-injected with monocytes, MARCOlow TAMs or MARCOhigh TAMs, PDX-derived tumors from each group were freshly dissociated into single cells and seeded in 96-well plates at 1–100 cells/well. Cells were treated with 5 Gy
ionizing radiation using the IBL 437C blood irradiator (CIS Bio International, Saclay,
France). After 2 weeks, each well was examined for neurosphere formation. The LDA
clonogenic index is calculated as the inverse of the x-intercept of the regression between the number of wells without spheres and the number of cells seeded. The frequency of stem-like clonogenic cells was determined using Extreme Limiting Dilution
Analysis (http://bioinf.wehi.edu.au/software/elda/).
In vitro tube formation assay

The tube formation assay was carried out using HUVECs to evaluate the angiogenic effects of TAMs. First, growth factor-free Matrigel (Corning Inc., Corning, NY, USA) was
added to a 96-well plate and incubated at 37 °C for 30 min. HUVECs were cultured
with each of the previously prepared CMs. Cells from each group (2 × 104/well) were
seeded in the Matrigel-pre-coated wells and incubated in a 5% CO2 incubator. The formation of tubular structures was assessed within 4 h by measuring the tube length
under a microscope (N = 3 fields/well) and was quantitated using ImageJ software.
Multiplex IHC

Multiplex staining was performed using an Opal 7 Immunology Discover kit
(OP7DS1001KT, PerkinElmer, Waltham, MA, USA) according to the manufacturer’s
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protocol. Slides were deparaffinized in xylene and rehydrated in ethanol. Antigen retrieval was performed in AR9 buffer by microwave treatment. Antibodies against the
following proteins were used: CD68, PPARG, BATF, SPI1, MARCO, and YKL-40. The
primary antibodies were incubated for 30 min in a humidified chamber at room
temperature, followed by detection using a mouse/rabbit SuperPicture Polymer Detection Kit. The primary antibodies were visualized using Opal Fluorophore Working Solution, after which the slides were placed in AR9 buffer and again subjected to
microwave treatment. The slides were examined using VECTRA 3.0 Automated Quantitative Pathology Imaging System (PerkinElmer). InForm image analysis software (PerkinElmer) was used to analyze the spectra of all fluorophores.
Isolation of mouse peritoneal macrophages

Peritoneal macrophages were obtained under sterile conditions 3 days after the intraperitoneal injection of 1–5% thioglycolate into the abdominal cavity of nude mice. The
cells were harvested by washing the peritoneal cavity with cold PBS (Gibco). Cells were
centrifuged and resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Gibco)
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Sigma-Aldrich). The cells were allowed to adhere for 4 h, washed to remove non-adherent cells,
and cultured in DMEM supplemented with 1% penicillin/streptomycin.
Overexpression lentivirus production and infection

Overexpression constructs were generated into lentivirus. Briefly, 3–4 × 106 293 T cells
were seeded in 100-mm culture dishes for 24 h prior to co-transfection with 4.5 μg of
lentivirus construct (pHRST-IRES-Pparg), 3 μg of psPAX2 (Paired box gene 2), and
1.5 μg of pMD2.G using 27 μg of Lipofectamine 2000. The media were changed after 6
h and the supernatant containing the lentivirus was harvested 48 h after the transfection. Viral particles were concentrated and purified using a Lenti-X-concentrator. Cells
were infected with lentivirus in the presence of 6 μg of polybrene. eGFP was used as a
fluorescent marker to distinguish successfully infected populations. Empty construct
was used as control for all experiments.
Statistical analysis

All data were expressed as the mean ± standard deviation (SD) or ± standard error of
the mean (SEM) based on at least two or three independent experiments. Student’s
two-tailed t test or analysis of variance (ANOVA) was used to determine the statistical
significance between two groups or more of continuous variables. Fisher’s exact test
was used to determine the statistical significance between two groups of categorical
data. Log-rank tests were used for survival analyses. A value of P < 0.05 was considered
statistically significant.
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